{"id":"aticaprant-therapeutic-dose","_chembl":{"chemblId":"CHEMBL1921847","moleculeType":"Small molecule","molecularWeight":"418.51"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Kappa opioid receptor (KOR)","explanation":"Aticaprant is a selective kappa opioid receptor antagonist. By blocking KOR, it prevents the dysphoric and stress-inducing effects mediated by this receptor system. This mechanism represents a novel approach to treating depression that differs from traditional monoamine-based antidepressants.","oneSentence":"Aticaprant blocks kappa opioid receptors in the brain, potentially improving mood regulation and reducing depressive symptoms."},"_scrapedAt":"2026-03-28T04:56:00.268Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123656,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"esketamine","brand":"Spravato","company":"Janssen","rationale":"Novel mechanism antidepressant for treatment-resistant depression"},{"name":"brexanolone","brand":"Zulresso","company":"Sage Therapeutics","rationale":"Novel mechanism antidepressant targeting GABA receptors"},{"name":"zuranolone","brand":"Zurzuvae","company":"Sage Therapeutics","rationale":"Oral neuroactive steroid for major depressive disorder"}],"description":"Aticaprant is an investigational kappa opioid receptor antagonist being developed by Janssen Research & Development for the treatment of major depressive disorder. The drug works by blocking kappa opioid receptors, which may help regulate mood and emotional responses in patients with depression.","indications":{"approved":[{"status":"investigational","condition":"Major Depressive Disorder","patientPopulation":"Adults with inadequate response to antidepressants"}]},"trialDetails":[{"nctId":"NCT05387759","phase":"PHASE1","title":"A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-05-30","conditions":"Healthy","enrollment":60},{"nctId":"NCT01913535","phase":"PHASE2","title":"Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2013-09-12","conditions":"Treatment Resistant Depression","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-67953964"],"phase":"phase_1","status":"active","brandName":"Aticaprant Therapeutic Dose","genericName":"Aticaprant Therapeutic Dose","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","firstApprovalDate":"","aiSummary":"Aticaprant is a small molecule kappa opioid receptor antagonist, classified as an antagonist. The therapeutic dose of aticaprant has been studied in clinical trials for treatment-resistant depression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}